Clinical Trial Update: Niraparib + Dostarlimab In BRCA Mutated Breast Cancer [Phase 2]

View source ↗

Summary

Clinical trial update describes a Phase 2 study at Dana-Farber Cancer Institute evaluating Niraparib plus Dostarlimab in BRCA-mutated breast cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING